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Gemcitabine and oxaliplatin (GEMOX) are active as first-line therapy against advanced pancreatic cancer. This study aims to evaluate
the activity and tolerability of this combination in patients refractory to standard gemcitabine (GEM). A total of 33 patients (median
age of 57) were included with locally advanced and metastatic evaluable diseases, who had progressed during or following GEM
therapy. The GEMOX regimen consisted of 1000mgm
 2 of GEM at a 100-min infusion on day 1, followed on day 2 by 100mgm
 2
of oxaliplatin at a 2-h infusion; a cycle that was given every 2 weeks. All patients received at least one cycle of GEMOX (median 5;
range 1–29). Response by 31 evaluable patients was as follows: PR: 7/31(22.6%), s.d. X8 weeks: 11/31(35.5%), s.d. o8 weeks:
1/31(3.2%), PD: 12/31(38.7%). Median duration of response and TTP were 4.5 and 4.2 months, respectively. Median survival was
6 months (range 0.5–21). Clinical benefit response was observed in 17/31 patients (54.8%). Grade III/IV non-neurologic toxicities
occurred in 12/33 patients (36.3%), and grade I, II, and III neuropathy in 17(51%), 3(9%), and 4(12%) patients, respectively. GEMOX is
a well-tolerated, active regimen that may provide a benefit to patients with advanced pancreatic cancer after progression following
standard gemcitabine treatment.
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Locally advanced and metastatic (MET) pancreatic adenocarcino-
mas carry a very poor prognosis. In patients treated with the
standard palliative treatment gemcitabine (GEM), median survival
still remains only 6 months (Burris et al, 1997). Over the last
several years, many trials have been designed combining GEM with
various other drugs to treat chemo-naive patients, with the aim to
improve overall survival (OS) (Table 1). Unfortunately, none of the
GEM-based combinations studied so far have reached that
objective, with the exception of GEM plus Erlotinib, which showed
a slight increase in OS to 6.4 months (Moore et al, 2005). However,
some trials – mainly those using platinum based combinations –
have shown an increase in response rate (RR) and time to
progression (TTP) (Table 1).
Unsurprisingly, the combination of GEM administered at a fixed
dose rate (FDR) together with oxaliplatin (OX) is being tried more
and more. It has become apparent that a FDR of 10mgm
 2min
 1
GEM is the optimal infusion speed to achieve the best conversion
rate of active phosphorylated gemcitabine, providing a two-fold
increase in intracellular gemcitabine triphosphate concentration
(Tempero et al, 2003). Tempero et al have shown that when doing
this, median survival was 8.0 months in the FDR arm (P¼0.013),
and only 5.0 months in the standard arm (30-min infusion). In
addition, at this infusion rate, GEM can be safely combined with
oxaliplatin, with no overlapping toxicity. This combination
appears to produce a sequence-dependent synergy of activity
when exposing tumour cells firstly to GEM and then 24h later with
oxaliplatin (Faivre et al, 1999).
The combination of GEM and oxaliplatin (GEMOX regimen) has
been reported by Louvet et al, to be active in first-line therapy
against advanced and metastatic pancreatic cancer. GEMOX has
also been shown to provide significantly better RR, clinical benefit
response (CBR) and period-free survival (PFS) than GEM alone
(Louvet et al, 2005). Furthermore, toxicity with this combination is
limited (Louvet et al, 2002).
The GEMOX combination was shown to have a survival benefit
of an additional 2 months, but this difference was not significant.
Possible causes of this could be the lack of power in the statistical
assumption, the inclusion of a high number of locally advanced
diseases (LAD), and the proportion of second-line therapy using a
platinum-based regimen.
However, in light of these interesting results, there are still no
guidelines or recommendations for selecting treatment for patients
progressing after GEM therapy; nor are there any reports of
regimens with demonstrated activity that would enable one to
justify one approach over another.
Consequently, we designed a multicentre phase II feasibility
study whose primary aim was to evaluate activity and tolerability
of the GEMOX regimen as second-line chemotherapy in gemcita-
bine-refractory advanced and metastatic pancreatic cancer.
Secondary aims of the study included evaluation of TTP and
overall survival.
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sPATIENTS AND METHODS
Patient eligibility
The study has been approved by the ethics committees of each
participating centre.
A total of 33 patients were eligible in four Belgian academic
hospitals. Inclusion criteria were: histologically proven locally
advanced or metastatic pancreatic adenocarcinoma, and progres-
sive disease during or within 3 months of gemcitabine as first-line
therapy or in adjuvant setting (including combination with
radiation). The disease had to be measurable according to modified
RECIST criteria (Therasse et al, 2000). All patients signed a written
informed consent to participate, were over 18 years old, had a
World Health Organization (WHO) performance status (PS) of
0, 1 or 2, and a life expectancy of more than six weeks (due to
bad prognosis of the disease). Adequate bone marrow (ANCX
1.5 10
9L
 1, platelets X100 10
9L
 1,H bX9gdl
 1), liver func-
tion (AST, ALT p2 ULN, total bilirubin p1.5 ULN), and renal
function (serum creatinin p2mgdl
 1) were required.
Previous or concomitant malignancy, cystic or neuroendocrine
tumours, and peripheral neuropathy (regardless of origin) were
considered as exclusion criteria.
At the time of inclusion, all patients underwent clinical
examination. Weight, height and PS were carefully recorded, and
abdominal CT, chest X-ray and plasma CA19.9 measurement were
performed before GEMOX administration.
Treatment plan
GEMOX regimen (Louvet et al, 2002) consisted of 1000mgm
 2 of
GEM at a 100-min infusion on day 1 (infusion rate
10mgm
 2min
 1), followed on day 2 by 100mgm
 2 of oxaliplatin
at a 2-h infusion. This cycle was given every 2 weeks until
progression of the disease. Oxaliplatin was provided by Sanofi-
Synthelabo (Paris, France) on a compassionate use basis.
Dose modifications
Before each cycle, assessment of haematologic and nonhaemato-
logic toxicities were performed using the NCI-CTC toxicity scale
(version 2.0).
In cases of febrile neutropenia or bleeding due to thrombo-
cytopenia, treatment was permanently withheld.
In cases of non-neurologic toxicity above grade (gr) 2, the entire
next cycle was delayed until toxicity had declined to gr 2 or less.
After recovery, subsequent doses were reduced as follows: GEM
800mgm
 2 at an 80-min infusion and oxaliplatin 85mgm
 2 at a
2-h infusion.
If a gr 3 cumulative typical peripheral neuropathy appeared,
oxaliplatin was discontinued; in the case of gr 2, the dose was
reduced to 85mgm
 2. For laryngopharyngeal dysesthesia, oxali-
platin infusion was reduced and given 6h – and eventually stopped
if further symptoms occurred during the following cycles.
Concomitant therapies
During the entire treatment, patients could receive full suppor-
tive care: antiemetics (anti-5HT3), steroids, analgesics, anti-
biotics, and acid-secretion inhibitors were permitted at the
discretion of the physician in charge of the patient. No other
chemo-, immuno- or experimental therapy was allowed during
the study.
Follow-up
Until progression of the disease, Karnovsky Assessment (KA),
physical examination, and blood analysis (haematology and
chemistry tests) were performed before the administration of each
cycle.
NCI-CTC toxicity scale (version 2.0) haematologic, non-
haematologic, and neurologic (Sanofi scale) toxicities were care-
fully recorded, as well as late toxicities, if any.
Clinical benefit was evaluated weekly, and was based on KS
assessment, weight measurement, evaluation of pain intensity
(using a visual analogue scale), and analgesic consumption.
Patients were asked to fill out a daily diary, which was reviewed
during each patient’s weekly assessment.
Evaluation of the tumour response was performed every four
cycles (or at anytime if there was clinical evidence of progression)
using modified RECIST criteria. Treatment was stopped at
progression of the disease.
Patients were followed until death.
Table 1 Recent randomised phase III studies using gemcitabine-based combinations in first-line therapy
Regimen Authors OS (months) RR (%) TTP (months)
GEM Burris et al (1997) 5.6* 5.4* 2.5
5-FU 4.41 0 0.9
GEM Louvet et al (2005) 7.1 16.7 3.7
GEMOX 9.0 28.7* 5.8
GEM O’Reilly et al (2004) 6.2 6.3 3.8
GEM-DX 6.7 8.2 3.7
GEM Rocha Lima et al (2004) 6.6 4.4 3.0
GEM-CPT11 6.3 16.1* 3.4
GEM Heinemann et al (2003) 6.0 2.5
GEM-CDDP 8.3 4.6
GEM Richards et al (2004) 6.3 9.1 3.6
GEM-pemetrexed 6.2 18.3* 5.2*
GEM Moore et al (2005) 5.91 8.0 3.55
GEM-Erlotinib 6.4* 9.0 3.75
Recent randomised phase III studies using gemcitabine-based combinations in first-line therapy. *Po0.05.
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The number of the patients required for the study has been
determined according to a two-stage Simon design. The target
enrolment was estimated to be 33 patients, and all analyses were
performed on the intention-to-treat population.
The minimum target activity level was 10% and early disconti-
nuation of the trial was planned in the case of only two or fewer
patients responding to treatment in the first 27 patients assessed.
This reduces the chance of inadvertently rejecting a true response,
or including a response rate below a certain standard. The trial
design, therefore, ensures that (i) there is no more than a 10%
chance that a treatment with a true response rate (25% or more) is
rejected, and (ii) that there is no more than a 10% probability that a
response rate of 10% or less would be accepted.
The primary end point of the study was activity measured
by RR and the feasibility of this second-line combination, where
feasibility was defined as toxicity and tolerance.
In addition, as secondary end points, we evaluated the clinical
benefit response, time to progression (TTP), and survival. Survival
was calculated from the start of GEMOX administration until the
death of the patient.
Statistical analysis was performed using the SPSS program
(SPSS, Chicago, IL, USA).
RESULTS
Patient’s population
A total of 33 patients (17 men and 16 women) with a median age of
57 (range 27–76), and WHO PS scores of 0/1/2 (12, 17, and four
patients, respectively) were included in a 12-month period. There
were 12(35%) with locally advanced disease and 21(65%) with
metastatic measurable disease. All 33 patients had previously
progressed during or following GEM-based therapy (GEM alone:
14 patients, GEMþother drug: 10 patients, and GEMþradiation
(RT): nine patients – including six adjuvant treatments after
surgery, where all patients showing recurrence after adjuvant
therapy (ADJ) discontinuation did so within 3 months). No patient
received gemcitabine as a fixed dose rate infusion during the first-
line treatment. Detailed patient demographics and prior therapy
are listed in Table 2.
Treatment completion and dose reductions
All patients received at least one cycle of GEMOX. A total of 208
cycles were administrated, with a median number of five cycles
given (range 1–29 cycles).
Eleven cycles were delayed due to gr 3 or 4 toxicities (described
in Table 3). After recovery from toxicity, subsequent cycles were
administered at reduced doses in 11 patients, and no additional
delay or dose reduction was necessary. Of the 208 cycles given,
29(13.9%) were administered at reduced doses.
Definitive withdrawn of treatment due to gr 3 peripheral
neuropathy occurred in four patients (12%) after 8, 8, 9, and 10
cycles of GEMOX.
Toxicity
One toxic death was reported. This was due to febrile neutropenia
that occurred after five cycles of GEMOX (without any previous
haematologic toxicity). This patient did have a response to
GEMOX after four cycles of treatment, but this was, of course,
not confirmed and not considered as a PR.
Haematologic and nonhaematologic toxicities are described in
Table 3.
One gr 4 toxicity was reported, consisting of febrile neutropenia
that lead to the death of the patient. Gr 3 haematologic toxicities
were observed in 8/33 patients (24%), consisting of neutropenia
(3), anaemia (2), and thrombopenia (3). Gr 3 nonhaematologic
toxicity occurred only in three patients (11%): nausea (two
patients) and vomiting (one patient).
Grade 1, 2, and 3 peripheral neuropathy were observed in
17(51%), 3(9%), and 4(12%) of 33 patients, respectively.
The total number of gr 3–4 toxicities recorded was 16 patients
(48%).
Overall, the regimen was well tolerated.
Table 2 Patients’ demographics and prior therapy
Characteristics n
Men/women 17/16
PS 0/1/2 12/17/4
LAD/MET 12/21
Adjuvant RT-CT 6
Prior therapy
RT-CT 3
GEM 14
GEM-PX 7
GEM-CDDP 2
Ralitrexed-GEM 1
Patients’ characteristics and first line-therapy received. MET: metastatic disease; LAD
locally advanced disease.
Table 3 Reported haematologic and nonhaematologic toxicities
n¼33 Neutropenia Anaemia Thrombopenia Total
Haematologic toxicity
Grade 1 1 3 6 10
Grade 2 4 0 0 4
Grade 3 3 2 3 8
Grade 4 1 0 0 1
All grades 9 5 9 23
n¼33 Nausea Vomiting Diarrhea Fatigue Neurotox Total
Nonhaematologic and neurologic toxicity
Grade 1 5 4 0 7 17 33
Grade 2 3 3 1 4 3 14
Grade 3 2 1 0 0 4 7
Grade 4 0 0 0 0 — 0
All grades 10 8 1 11 24 54
Reported haematologic and nonhaematologic toxicities.
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Of the 33 patients, 31 were evaluable for response and clinical
benefit response.
Seven patients (22.6%) experienced a partial response (PR) that
was confirmed, with a median duration of this response of 4.5
months (range 1.5–16).
In all, 12 patients (38.7%) were stabilised (stable disease, s.d.),
whereby s.d. endured for more than 8 weeks in 11 patients (35.5%),
and for o8 weeks in 1/31 (3.2%).
Median TTP was 4.2 months. Median survival since the start of
GEMOX was 6 months (range 0.5–21). Median survival since the
start of first-line treatment was 12 months (range 3–34).
A clinical benefit response was observed in 17 evaluable patients
(54.8%).
Regarding the 16 patients who had progressed within 3 months
of previous first-line GEM, best responses were: 1 PR, 5 s.d. and 10
PD. Re-challenging this group of patients with GEMOX led to PR in
1/1, 3/5, and 3/10, respectively, and s.d. in four additional patients.
DISCUSSION
The present study reports, for the first time, the use of the GEMOX
regimen in gemcitabine-refractory, locally advanced and meta-
static pancreatic adenocarcinoma. Currently, in gemcitabine-
refractory patient, there is no data concerning the choice of the
second-line therapy. For these patients, we chose to assess the
GEMOX regimen based on its activity (28.7%) and tolerability
profile reported in first-line use (Louvet et al, 2005). The schedule
of administration and infusion rate within our study were similar
to previous preclinical and clinical data (Faivre et al, 1999;
Tempero et al, 2003). We chose to include LAD, because our trial
design was a feasibility phase II study, and not a phase III survival
trial.
The tolerability of GEMOX is well assessed as 59% of were
considered to be in poor condition (PS 1–2), where no major
toxicities were seen. Overall, treatment was well tolerated, and with
the exception of one gr 3 neuropathy and one febrile neutropenia,
no other toxic event led to treatment interruption. Acute
haematologic toxicity was limited, consisting mainly in gr 3
anaemia, thrombopenia and neutropenia. One toxic death was
reported due to a febrile neutropenia that occurred after five cycles
of GEMOX without any previous haematologic toxicity during the
four first administrations. Typical peripheral oxaliplatin-related
neuropathy was noted: half of the patients experienced a gr 1
neurotoxicity and four patients (12%) had developed gr 3
neuropathy leading to withdrawal of GEMOX treatment. In these
four particular patients, GEMOX was stopped after 8, 8, 9, and 10
cycles, respectively. Globally, these toxicity data are comparable to
those from other studies using GEMOX in first line (Table 4).
The activity of the regimen was good, achieving partial response
in 22.6% of and disease stabilisation for more than 8 weeks in
35.5% of patients. This activity is comparable to that observed in
first line by Louvet (28.7%) and to that observed in second line
using oxaliplatin (50mgm
 2 weekly)/LV/5-FU (Tsavaris et al,
2005). A 6-month survival can be expected in the setting of second-
line therapy, as supported by the findings of this study and other
phase II trials based with other drugs combinations (Table 5).
Manageable toxicity and good clinical benefit response rate were
also important valuable findings of this trial.
Our data also suggest that the addition of oxaliplatin to
gemcitabine may be active and effective, even after progression
or failure under the latter drug. Currently, it is difficult to
differentiate between the relative role of each drug in overcoming
the tumour resistance to gemcitabine administered alone in a
standard 30-min regimen. The addition of oxaliplatin to gemci-
Table 4 Comparison of toxicity profiles (values are expressed in %)
Toxicity (in %)
Demols
(second line) Louvet (2) Heinemann (10)
Gr3 neuropathy 12 19 ND
Gr3-4 neutropenia 12.5 14 5
Gr3-4 anaemia 6 8 0
Gr3-4
thrombopenia
91 7 1 5
Gr3-4 nausea and
vomiting
91 1N D
Comparison of toxicity profiles (values are expressed in %). ND: not determined.
Table 5 Phase II and III trials in second-line therapy
Regimen Authors and phase Number of patients PR (%) s.d. (%) Median OS (weeks)
OX/LV/5-FU Tsavaris 30 23.3 30 25
Phase II
OX Androulakis et al (2005) 18 0 16.7 ND
Phase II
CPT-11/ralitrexed vs ralitrexed Ulrich-Pur et al (2003) 38 16 ND 26
Ramdomised II 0 ND 17
Paclitaxel Oettle et al (2000) 18 5.5 27.7 17.5
Phase II
Capecitabine/erlotinib Blaszkowsky et al (2005) 30 11 57 27
Phase II
OX/FA/5-FU Oettle et al (2000) 46 ND ND 21
Vs BSC Phase III 10
CPT-11/FA/5-FU Ng et al (2005) 15 0 38 14
Phase II
GEMOX Demols
Phase II 33 22.6 38.7 25
Phase II and III trials in second-line therapy. BSC: best supportive care; ND: not determined.
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stabine on day 2 could explain this resensitisation of the tumour,
but the slower rate of infusion of gemcitabine versus how it was
administered in first-line might also play a role in this recovered
activity. Additional data is needed to determine what gives
GEMOX its incremental activity over GEM in second-line.
Results coming from the ECOG 6201 trial, comparing gemcita-
bine as a standard 30-min infusion, gemcitabine at a fixed-dose
rate, and the GEMOX regimen will determine the best way to
administer gemcitabine. It is anticipated that this trial will also
clarify the role of oxaliplatin when added to gemcitabine in chemo-
naive patients. The Louvet trial has shown a better activity profile
of the combination of these drugs versus monotherapy, but has
failed to demonstrate a clear statistically significant survival
advantage. These results are key to determine the place of
oxaliplatin in the management of advanced pancreatic cancer.
Recently, other data have suggested a beneficial role of oxali-
platin in second-line therapy using the OFF regimen (oxaliplatin/
folinic acid/5-FU 24h). The randomised CONKO 003 phase III trial
showed a statistically significant increase in overall survival when
giving OFF regimen in second line, as compared to best supportive
care (Oettle et al, 2005).
Nonetheless, many issues remain unanswered in the manage-
ment of pancreatic cancer. The need to determine prognostic and
predictive factors is essential to identify the best therapy for all
patients. The emergence of biological therapies will, in fact, require
such a prospective selection of patients based on these factors. The
combination of new biological agents with another cytotoxic, such
as oxaliplatin to gemcitabine could become a treatment standard.
In the setting of second-line therapy, a prospective well-designed
phase III trial would be useful to validate oxaliplatin-based
regimens. In this setting, GEMOX could be compared to BSC, or
to another oxaliplatin-based regimen; FOLFOX for example.
Our study, showing that the GEMOX regimen is active and well
tolerated after progression with standard gemcitabine therapy,
supports the beneficial role of this combination in advanced
pancreatic cancer.
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